AstraZeneca plc (NYSE:AZN) has received a consensus recommendation of “Buy” from the twenty-one research firms that are currently covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $38.12.
A number of research analysts have recently commented on the stock. BMO Capital Markets set a $40.00 price target on shares of AstraZeneca and gave the stock a “buy” rating in a report on Thursday, March 22nd. Leerink Swann upped their price target on shares of AstraZeneca from $36.00 to $38.00 and gave the stock a “market perform” rating in a report on Tuesday, February 6th. Sanford C. Bernstein upped their price objective on shares of AstraZeneca from $40.00 to $42.00 and gave the stock an “outperform” rating in a research note on Monday, February 5th. ValuEngine lowered shares of AstraZeneca from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, March 7th. Finally, Zacks Investment Research raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research note on Monday, January 22nd.
AZN stock opened at $35.79 on Wednesday. The company has a current ratio of 0.80, a quick ratio of 0.62 and a debt-to-equity ratio of 0.93. AstraZeneca has a twelve month low of $28.43 and a twelve month high of $36.70. The firm has a market cap of $89,715.17, a price-to-earnings ratio of 8.28, a PEG ratio of 1.84 and a beta of 0.62.
The company also recently declared a semiannual dividend, which was paid on Monday, March 19th. Shareholders of record on Friday, February 16th were given a dividend of $0.95 per share. This represents a dividend yield of 5.62%. The ex-dividend date was Thursday, February 15th. AstraZeneca’s payout ratio is 32.01%.
Institutional investors have recently made changes to their positions in the stock. Commerce Bank increased its holdings in AstraZeneca by 14.7% in the 4th quarter. Commerce Bank now owns 11,548 shares of the company’s stock worth $400,000 after buying an additional 1,480 shares during the period. M&T Bank Corp increased its holdings in AstraZeneca by 0.5% in the 4th quarter. M&T Bank Corp now owns 317,119 shares of the company’s stock worth $11,003,000 after buying an additional 1,676 shares during the period. TIAA FSB increased its holdings in AstraZeneca by 6.7% in the 4th quarter. TIAA FSB now owns 27,087 shares of the company’s stock worth $940,000 after buying an additional 1,692 shares during the period. First Allied Advisory Services Inc. increased its holdings in AstraZeneca by 7.6% in the 4th quarter. First Allied Advisory Services Inc. now owns 23,845 shares of the company’s stock worth $825,000 after buying an additional 1,694 shares during the period. Finally, Logan Capital Management Inc. increased its holdings in AstraZeneca by 7.0% in the 4th quarter. Logan Capital Management Inc. now owns 26,040 shares of the company’s stock worth $904,000 after buying an additional 1,710 shares during the period. 15.14% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: “Brokerages Set AstraZeneca plc (AZN) Target Price at $36.32” was originally posted by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this piece of content on another site, it was copied illegally and republished in violation of United States & international copyright laws. The legal version of this piece of content can be read at https://stocknewstimes.com/2018/04/16/brokerages-set-astrazeneca-plc-azn-target-price-at-36-32.html.
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.